ArticleSurgical endoscopy2026
Clinical outcomes of esophageal squamous cell carcinoma with pathological complete response after neoadjuvant chemoradiotherapy and surgery.
Article in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeoadjuvant chemoradiotherapy (NCRT) followed by surgery is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). Pathological complete response (pCR) is a key prognostic indicator, yet clinical outcomes and recurrence patterns in ESCC patients achieving pCR warrant further investigation.
methodsWe retrospectively analyzed patients with cT2-4aN0-3 ESCC who underwent NCRT followed by esophagectomy between 2014 and 2022. Patients were stratified into pCR (ypT0N0) and non-pCR groups. Survival and recurrence outcomes were assessed using Kaplan-Meier and Cox regression analyses.
resultsAmong 136 patients (mean age 59.1 ± 7.2 years, 90.4% male), 39 (28.7%) achieved pCR. With a median follow-up of 30 months, the 5-year overall survival (OS) rate was 81.6% in the pCR group versus 39.2% in the non-pCR group (p < 0.001), and the 5-year disease-free survival (DFS) rate was 70.1 vs. 31.0%, respectively (p < 0.001). Recurrence occurred in 26.3% of pCR patients, significantly lower than the 65.9% in non-pCR patients (p < 0.001). Multivariate analysis identified pCR as an independent favorable prognostic factor for OS (HR 0.351, 95% CI 0.121-0.980, p = 0.040) and ypTNM stage for both OS (HR 1.516, 95% CI 1.114-2.063, p = 0.006) and DFS (HR 1.733, 95% CI 1.381-2.174, p = 0.001).
conclusionAchieving pCR after NCRT is associated with significantly improved survival in ESCC patients. However, recurrence still occurs in a notable proportion of pCR patients, underscoring the need for further risk stratification and exploration of adjuvant strategies even in this favorable response group.
Indexed as
Identifiers
41774194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.